Solid Tumors in Children: Advances and Challenges

A special issue of Children (ISSN 2227-9067). This special issue belongs to the section "Oncology and Hematology".

Deadline for manuscript submissions: closed (31 December 2021) | Viewed by 2996

Special Issue Editors

E-Mail Website
Guest Editor
Pediatric Surgery Unit, Department of Emergencies and Organ Transplantation, Azienda Ospedaliero-Universitaria Consorziale, Ospedale Pediatrico Giovanni XXIII, 70123 Bari, Italy
Interests: pediatric surgery, pediatric oncology

E-Mail Website
Guest Editor
Pediatric Surgery, Department of Women's and Children's Health, University-Hospital of Padua, 35128 Padua, Italy
Interests: pediatric oncologic surgery; rare solid tumors; neuroblastoma; gonadal tumors; adrenocortical tumors; tumor registries; general pediatric surgery

E-Mail Website
Guest Editor
Department of Pathology, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy
Interests: pediatric pathology; pediatric oncology

Special Issue Information

Dear Colleagues,

In recent years, major changes have occurred in the diagnostic–therapeutic approach to solid tumors in children and adolescents, which have determined a consistent improvement in survival, minimizing the exposure to chemo- and radiotherapy side effects. 

The high participation in cooperative trials has been proven to play a fundamental role in the exploration of new concepts in all fields of pediatric cancer (genetic, histology, biology), which has allowed for the identification of new treatment options, such as biologic targeted therapies, that could be used in combination with traditional chemotherapy regimens or radiation.

In this context, pediatric surgeons and radiologists play a leading role in different aspects of the disease course, and over the years, they have been committed to searching for more advanced, minimally invasive techniques, to make the management of children easier.

In this Special Issue, the authors cover the latest clinical and basic science innovations in the more common solid tumors in children and discuss original tools that are being developed for defining a diagnosis or performing surgery, preventing long-term consequences. 

For each tumor, we would like to consider the possible benefits of minimally invasive surgery (laparoscopy, thoracoscopy and robotic), the use of interventional radiology techniques for the identification and treatment of metastases, the use of Green Indocyanine for metastases or residual tumors, the role of PET CT or PET RMI for the identification of lymph nodes and, in particular, the sentinel node in soft-tissue sarcoma. We would also like to mention the techniques of fertility preservation and the development of surgical quality guidelines.

Prof. Patrizia Dall'Igna
Dr. Calogero Virgone
Prof. Rita Alaggio
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Children is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • neuroblastoma
  • Wilms tumor
  • rhabdomyosarcoma
  • non-Rhabdo soft-tissue sarcoma (NRSTS)
  • germ cell tumors
  • hepatoblastoma
  • chemotherapy
  • surgery
  • radiology
  • interventional radiology
  • radiotherapy

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


8 pages, 431 KiB  
Brief Report
Treatment of Pediatric Inflammatory Myofibroblastic Tumor: The Experience from China Children’s Medical Center
by Youhong Dong, Kashif Rafiq Zahid, Yidi Han, Pengchao Hu and Dongdong Zhang
Children 2022, 9(3), 307; - 24 Feb 2022
Cited by 7 | Viewed by 2331
Background: Inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal tumor with intermediate malignancy that tends to affect children primarily. To date, no standardized therapies exist for the treatment of IMT. This study aimed to share experience from China Children’s Medical Center for the [...] Read more.
Background: Inflammatory myofibroblastic tumor (IMT) is a rare mesenchymal tumor with intermediate malignancy that tends to affect children primarily. To date, no standardized therapies exist for the treatment of IMT. This study aimed to share experience from China Children’s Medical Center for the explorative treatment of IMT. Methods: Patients with newly diagnosed IMT between January 2013 and December 2018 were included. Patients were grouped according to surgical margins and Intergroup Rhabdomyosarcoma Study Group (IRSG) staging. The clinical characteristic, therapeutic schedules, treatment response and clinical outcome were described. Results: Six patients were enrolled in this study, including two boys and four girls, with a median age of 57 months (range 10–148 months). Among them, five patients were anaplastic lymphoma kinase positive. Four patients achieved complete remission and two patients attained partial remission after treatment with this protocol. All patients were alive after a median follow-up of 4 years (range 3–7 years). The most common treatment-related adverse reaction was myelosuppression. Conclusion: In this study, we demonstrated that IMT has a good prognosis and the treatment selected according to risk stratification was effective and feasible. Full article
(This article belongs to the Special Issue Solid Tumors in Children: Advances and Challenges)
Show Figures

Figure 1

Back to TopTop